Benedicte Recolin

Leveraging In Vitro Models to Support ADC Preclinical Safety Assessments to Accurately Predict & Quantify Clinical Toxicity Profiles 

• Applying advanced in vitro models to complement ADC safety strategy alongside in vivo preclinical models
• Integrating bioanalytical methods with in vitro toxicity to improve early-stage clinical toxicity predictions
• Assessing key toxicities commonly observed in clinical settings to prioritize and select the safest ADC molecules